Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1

Biochemical and Biophysical Research Communications

Volumn 291, Issue 5, 2002, Pages 1302-1308

  Hinke, Simon A ^a   Pederson, Raymond A ^a   McIntosh, Christopher H S ^a   Kühn Wache, Kerstin ^b   Hoffmann, Torsten ^b   Demuth, Hans Ulrich ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b PROBIODRUG AG   (Germany)

Author keywords

BIAcore; CD 26; DPP IV; Entero insular axis; Incretin; MALDI TOF mass spectrometry; Surface plasmon resonance

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; METFORMIN;

ARTICLE; BINDING AFFINITY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME DEGRADATION; HYDROLYSIS; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN IMMOBILIZATION; PROTEIN PROTEIN INTERACTION; SURFACE PLASMON RESONANCE;

SUIDAE;

EID: 0036298693     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2002.6607     Document Type: Article

References (24)

1. Pharmacologic therapy for type 2 diabetes mellitus
2. New approaches in the treatment of type 2 diabetes
3. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
4. The entero-insular axis
5. Peptide hormone regulation of islet cell
6. Dipeptidylpeptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum
7. Investigation of GIP1-42 and GLP-1 7-36 degradation in vitro by dipeptidyl peptidase IV (DPIV) using Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS): A novel kinetic approach
8. Improved glucose tolerance in zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide
9. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor ile-thiazolidide
10. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice
11. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptides 1 in the anesthetized pig
12. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats
13. Metformin
14. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus
15. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects
16. Effects of metformin on baseline and oral glucose-induced glucagon-like peptide-1 (GLP-1) in obese non-diabetic subjects
17. Kinetics of dipeptidyl-peptidase IV
18. Dipeptidyl peptidase IV degradation of glucagon: Characterization of glucagon degradation products and DPIV resistant analogs
19. Kinetic analysis of enzymatic and nonenzymatic degradation of peptides by MALDI-TOF MS
20. Clinical pharmacokinetics of metformin
21. Effects of metformin on intestinal and pancreatic endocrine secretion in type 2 (non-insulin-dependent) diabetes
22. The effect of metformin treatment on gastric acid secretion and gastrointestinal hormone levels in normal subjects
23. The glucagon-like peptides